William L. Ashton Joins Galena Biopharma's Board of Directors

William L. Ashton Joins Galena Biopharma's Board of Directors

LAKE OSWEGO, Ore., May 1, 2013 (GLOBE NEWSWIRE) -- Galena Biopharma
(Nasdaq:GALE), a biopharmaceutical company developing innovative, targeted
oncology treatments that address major unmet medical needs to advance cancer
care, today announced the addition of William L. Ashton to the Company's Board
of Directors.

Mr. Ashton is a senior executive with more than twenty-eight years of
experience in biotechnology and pharmaceutical leadership and management. Most
recently, at Amgen, Inc., he served as Vice President of corporate and
government affairs and Vice President of sales, and was directly responsible
for product launches, as well as key government agencies including Centers for
Medicare and Medicaid Services, Office of Inspector General, General
Accounting Office, Office of Management and Budget, and MedPAC.

"Bill brings an enormous wealth of commercial experience and expertise in
pharmaceutical sales, leadership and corporate affairs that will be invaluable
to Galena as we move forward into commercialization this year," said Mark J.
Ahn, Ph.D., President and Chief Executive Officer of Galena Biopharma. "We
look forward to his contributions and guidance in establishing Abstral® as the
best in class leader in breakthrough cancer pain, as well as preparing for
NeuVax™ commercialization."

After retiring from Amgen, Mr. Ashton joined the University of the Sciences in
Philadelphia where he currently serves as Associate Provost and Senior Vice
President of Strategic Business Development, Founding Dean, Mayes College of
Healthcare Business and Policy, and Assistant Professor of Pharmaceutical
Business.

Mr. Ashton is on the boards of the National Osteoporosis Foundation, Friends
of the National Library of Medicine (NIH), and a commissioner for the Medical
Representatives National Certificate Commission. He currently serves on the
board of Sucampo Pharmaceuticals. He received his Bachelor of Science from
California University of Pennsylvania and his Master of Science from the
University of Pittsburgh.

"Galena has made exceptional progress over the last few years, and I am
excited to join the Board of Directors as the company initiates
commercialization. With NeuVax enrolling its Phase 3 trial and the
commercialization of Abstral expected this year, I look forward to providing
my support and guidance as we work to enhance the treatment of cancer
patients," added William L. Ashton.

About Galena Biopharma

Galena Biopharma, Inc. (Nasdaq:GALE) is a Portland, Oregon-based
biopharmaceutical company developing innovative, targeted oncology treatments
that address major unmet medical needs to advance cancer care. For more
information please visit us at www.galenabiopharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 relating to Galena's
expectations for commercialization of Abstral® and the development of Galena's
NeuVax product candidate. These forward-looking statements are subject to a
number of risks, uncertainties and assumptions, including the possibility that
Galena's commercialization of Abstral may be delayed or prove unsuccessful.
Galena's business and operations and the development of its product candidates
also are subject to the risks and uncertainties identified under "Risk
Factors" in Galena's Annual Report on Form 10-K for the year ended December
31, 2012 filed with the SEC. Actual results may differ materially from those
contemplated by these forward-looking statements. Galena does not undertake to
update any of these forward-looking statements to reflect a change in its
views or events or circumstances that occur after the date of this press
release.

CONTACT: Remy Bernarda
         Senior Director, Communications
         +1 (503) 400-6995
         rbernarda@galenabiopharma.com

Galena Biopharma, Inc.